# Combination of Erlotinib and Bevacizumab as Second-line Treatment in Patients With Non-small Cell Lung Cancer

> **NCT00749567** · PHASE2 · TERMINATED · sponsor: **Hellenic Oncology Research Group** · enrollment: 13 (actual)

## Conditions studied

- Non-small-cell Lung Cancer

## Interventions

- **DRUG:** Erlotinib
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT00749567
- **Lead sponsor:** Hellenic Oncology Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-07
- **Primary completion:** 2010-09
- **Final completion:** 2010-09
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Poor accrual
- **Last updated:** 2015-09-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00749567

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00749567, "Combination of Erlotinib and Bevacizumab as Second-line Treatment in Patients With Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00749567. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*